KAS
BCRX icon

Kemnay Advisory Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Kemnay Advisory Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6K Buy
2,264
+224
+11% +$2.03K ﹤0.01% 667
2026
Q1 		$19.4K Buy
+2,040
New +$15.8K ﹤0.01% 707

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Kemnay Advisory Services's BCRX Position: Q2 2026 in Review

Kemnay Advisory Services increased its BioCryst Pharmaceuticals (BCRX) stake by 11% in Q2 2026, buying an estimated $2.03K and bringing the position to 2,264 shares worth $22.6K. The position accounts for ﹤0.01% of the portfolio, ranked #667.

Kemnay Advisory Services first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Kemnay Advisory Services held 2,264 shares of BioCryst Pharmaceuticals worth $22.6K as of Q2 2026.
  • Kemnay Advisory Services bought 224 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.03K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #667 holding.
  • Kemnay Advisory Services first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.